Shares of Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) saw an uptick in trading volume on Tuesday . Approximately 80,436 shares changed hands during trading, an increase of 32% from the previous session’s volume of 60,844 shares.The stock last traded at $7.0350 and had previously closed at $7.30.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.
Check Out Our Latest Research Report on NNNN
Anbio Biotechnology Stock Performance
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Recommended Stories
- Five stocks we like better than Anbio Biotechnology
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
